- Report
- November 2023
- 262 Pages
Global
From €7239EUR$7,500USD£6,210GBP
- Report
- January 2024
- 175 Pages
Global
From €4826EUR$5,000USD£4,140GBP
- Drug Pipelines
- April 2024
- 60 Pages
Global
From €1930EUR$2,000USD£1,656GBP
- Report
- April 2024
- 30 Pages
Global
From €3426EUR$3,550USD£2,939GBP
- Report
- April 2024
- 30 Pages
Global
From €3426EUR$3,550USD£2,939GBP
- Report
- April 2024
- 30 Pages
Global
From €3137EUR$3,250USD£2,691GBP
- Report
- April 2024
- 30 Pages
Global
From €3426EUR$3,550USD£2,939GBP
- Report
- April 2024
- 30 Pages
Global
From €3426EUR$3,550USD£2,939GBP
- Report
- April 2024
- 30 Pages
Global
From €3426EUR$3,550USD£2,939GBP
- Report
- April 2024
- 30 Pages
Global
From €3426EUR$3,550USD£2,939GBP
- Report
- April 2024
- 30 Pages
Global
From €3137EUR$3,250USD£2,691GBP
- Report
- February 2024
- 120 Pages
Asia Pacific
From €4778EUR$4,950USD£4,098GBP
- Report
- December 2021
- 245 Pages
Global
From €2654EUR$2,750USD£2,277GBP
€5309EUR$5,500USD£4,554GBP
- Report
- June 2021
- 213 Pages
Global
From €2654EUR$2,750USD£2,277GBP
€5309EUR$5,500USD£4,554GBP
- Report
- April 2018
- 80 Pages
Global
From €5743EUR$5,950USD£4,926GBP
- Report
- January 2022
- 200 Pages
Global
From €7239EUR$7,500USD£6,210GBP
- Report
- January 2022
- 60 Pages
Global
From €3813EUR$3,950USD£3,270GBP
- Report
- April 2022
- 120 Pages
Global
From €2413EUR$2,500USD£2,070GBP
- Report
- August 2022
United States
From €1872EUR$1,940USD£1,606GBP
- Report
- August 2022
Global
From €956EUR$990USD£820GBP
The Hepatitis B Drug market is a subset of the Infectious Diseases Drugs market. It is composed of drugs used to treat the hepatitis B virus, a virus that can cause serious liver damage. These drugs are used to reduce the amount of virus in the body, reduce the risk of liver damage, and improve overall health. Common drugs used to treat hepatitis B include interferon, nucleoside analogues, and protease inhibitors.
The Hepatitis B Drug market is highly competitive, with many companies offering treatments. Some of the major players in the market include Gilead Sciences, Merck & Co., AbbVie, Bristol-Myers Squibb, and GlaxoSmithKline. Show Less Read more